Clinical Trials on Gastroesophageal Reflux Disease in Japan

Total 6959 results

Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients

Gastroesophageal Reflux Disease

Japan
Showa Inan General Hospital

Withdrawn

Elemental Diets vs. Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation

Gastro-oesophageal Reflux

Japan
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Non-erosive Reflux Disease

Japan
Takeda

Completed

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Reflux Esophagitis

Japan
Showa Inan General Hospital

Recruiting

The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole

Gastroesophageal Reflux

Japan
Osaka University

Withdrawn

Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children

Gastroesophageal Reflux

Japan
Takeda

Completed

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Japan
Gunma University

Completed

MSG and Gastrointestinal Motility

Gastroesophageal Reflux

Japan
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Non-erosive Reflux Disease

Japan
AstraZeneca

Completed

S-CEI of Nexium in Paediatric Patients

Peptic Ulcer, Gastroesophageal Reflux

Japan
Eisai Inc.
Eisai Limited

Completed

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Taiho Pharmaceutical Co., Ltd.
UCB Pharma

Completed

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Gastroesophageal Reflux

Japan
Takeda

Completed

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Co., Ltd.

Completed

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Co., Ltd.

Completed

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Gastroesophageal Reflux Disease

Japan
Eisai Co., Ltd.

Completed

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Refractory Reflux Esophagitis

Japan
Takeda

Completed

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE)

Reflux Esophagitis

Japan
Hamilton Health Sciences Corporation
Tehran University of Medical Sciences; Tohoku University

Recruiting

Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting

Functional Dyspepsia | Peptic Ulcer | Gastro Esophageal Reflux | Normal Control

Canada, Iran, Islamic Republic of, Japan
AstraZeneca

Completed

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Reflux Esophagitis

Japan
Takeda

Completed

Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
AstraZeneca

Completed

Reflux Esophagitis Phase III Study (Initial Treatment)

Reflux Esophagitis

Japan
AstraZeneca

Completed

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis

Japan
AstraZeneca

Completed

Reflux Esophagitis Phase III Study (Maintenance Treatment)

Reflux Esophagitis

Japan
AstraZeneca

Completed

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Refractory Reflux Esophagitis

Japan
Astellas Pharma Inc

Completed

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

Gastroesophageal Reflux

Japan
Eisai Co., Ltd.

Completed

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Refractory Reflux Esophagitis

Japan
Amgen

Completed

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Cancer

Japan
AstraZeneca

Completed

A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Zollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)

Japan
AstraZeneca

Completed

Nexium Capsules Clinical Experience Investigation

Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome

Japan
Zeria Pharmaceutical

Completed

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Esophagitis, Reflux

Japan
M.D. Anderson Cancer Center

Recruiting

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Gastrostomy | GastroEsophageal Cancer | Gastric

United States, Japan, Korea, Democratic People's Republic of
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan
AstraZeneca

Completed

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis | Anastomotic Ulcer | Etc.

Japan
Millennium Pharmaceuticals, Inc.

Terminated

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Recurrent Gastric Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Advanced Gastrointestinal Carcinoma | Recurrent Gastrointestinal Carcinoma

Taiwan, Korea, Republic of, Japan
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AstraZeneca

Completed

Nexium Capsules RE Maintenance Specific Clinical Experience Investigation

Repeatedly Recurring Esophagitis | Relapsing Reflux Esophagitis

Japan
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Nanfang Hospital of Southern Medical University
LanZhou University; Chulalongkorn University; Beijing 302 Hospital; Xijing Hospital... and other collaborators

Recruiting

Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Compensated Cirrhosis (Pan-CHESS1801)

Compensated Liver Cirrhosis | Gastroesophageal Varices Bleeding

China, Japan, Indonesia, Thailand, Turkey
Amgen

Terminated

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, Taiwan, Spain, Austria, United States, France, Japan, Germany, Netherlands
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (CARMEN-GC01)

Adenocarcinoma Gastric | Gastrooesophageal Cancer

Japan, Belgium, Korea, Republic of, Spain, Russian Federation, Turkey
Toray Industries, Inc

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Japan
Kuhnil Pharmaceutical Co., Ltd.
Daiichi Sankyo Co., Ltd.

Terminated

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Taiwan, Japan, Korea, Republic of
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Japan, Korea, Republic of
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)

Gastric Cancer | Gastroesophageal Junction Cancer

Japan, Korea, Republic of, Taiwan, Singapore, United States
BeiGene

Active, not recruiting

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Gastric, or Gastroesophageal Junction Adenocarcinoma

United States, China, Spain, Korea, Republic of, Poland, Russian Federation, Taiwan, France, Turkey, Japan, Italy, United Kingdom, Puerto Rico
Eli Lilly and Company

Completed

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, Taiwan, Japan
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom

Clinical Trials on Gastroesophageal Reflux Disease in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations